SparingVision Presents Three Posters at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
SparingVision is pleased to announce that it has presented three posters highlighting the Company’s recent…
Press Release
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis…
SparingVision Announces Upcoming Poster Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2021 Virtual Annual Meeting
An abstract on rod-derived cone viability factor (RdCVF) in pig models of Retinitis Pigmentosa (RP)…
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
Three abstracts highlighting the company’s recent research into ocular diseases and its lead gene therapy…
SparingVision Conference Participation in H1 2021
SparingVision announces the conferences that its management team will be participating in in the first…
Dr. Daniel C. Chung appointed as Chief Medical Officer of SparingVision
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of…
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board Paris, January…
SparingVision Strengthens Management Team
• Dr. Florence Lorget to lead development sciences as Chief Development Sciences Officer • Dr.…
SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer
New investors include 4BIO Capital, UPMC Enterprises, Jeito Capital and Ysios Capital with additional investment…
SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retinal Dystrophies
Paris, June 30th, 2020 – SparingVision, a biotechnology company specializing in the research and development…
